Metformin in the era of new antidiabetics

Papers of special note have been highlighted as: • of interest

References

• 1. Wang L, Gao P, Zhang M et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24), 2515 (2017).
  MedlineGoogle Scholar
• 2. IDF Diabetes Atlas (9th Edition). (2019). https://www.diabetesatlas.org/en/
  Google Scholar
• 3. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 43(Suppl. 1), S14–S31 (2020). • It includes concepts about diabetes that should be known.
  MedlineGoogle Scholar
• 4. Guillausseau P-J, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian J-P. Abnormalities in insulin secretion in Type 2 diabetes mellitus. Diabetes Metab. 34, S43–S48 (2008).
  Medline CASGoogle Scholar
• 5. Emerging Risk Factors Collaboration, Sarwar N, Gao P et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet Lond. Engl. 375(9733), 2215–2222 (2010).
  MedlineGoogle Scholar
• 6. Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in Type 2 diabetic patients: a long-term follow-up study in Osaka District, Japan. Diabetes Res. Clin. Pract. 7(1), 33–40 (1989).
  Medline CASGoogle Scholar
• 7. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015).
  Medline CASGoogle Scholar
• 8. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017).
  Medline CASGoogle Scholar
• 9. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019).
  Medline CASGoogle Scholar
• 10. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in Type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019).
  Medline CASGoogle Scholar
• 11. Cannon CP, Pratley R, Dagogo-Jack S et al. Cardiovascular outcomes with ertugliflozin in Type 2 diabetes. N. Engl. J. Med. 383(15), 1425–1435 (2020).
  Medline CASGoogle Scholar
• 12. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019).
  Medline CASGoogle Scholar
• 13. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med. 375(4), 311–322 (2016).
  Medline CASGoogle Scholar
• 14. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 375(19), 1834–1844 (2016).
  Medline CASGoogle Scholar
• 15. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193), 121–130 (2019).
  Medline CASGoogle Scholar
• 16. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with Type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157), 1519–1529 (2018).
  Medline CASGoogle Scholar
• 17. Zelniker TA, Wiviott SD, Raz I et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in Type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation 139(17), 2022–2031 (2019).
  Medline CASGoogle Scholar
• 18. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 381(9), 841–851 (2019).
  Medline CASGoogle Scholar
• 19. Pasternak B, Wintzell V, Melbye M et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study. BMJ. 369, m1186 (2020).
  MedlineGoogle Scholar
• 20. Pasternak B, Wintzell V, Eliasson B et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43(6), 1326–1335 (2020).
  MedlineGoogle Scholar
• 21. Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41(2), 255–323 (2020). • Its comes from the European Society of Cardiology and the European Association for the study of Diabetes Task force and it aims to guide management of diabetes and prediabetes specifically in patients with cardiovascular disease.
  MedlineGoogle Scholar
• 22. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 43(Suppl. 1), S98–S110 (2020). • Its reading cannot be ignored, as it reflects the evidence and therapeutic practice recommendations of American Diabetes Association. It is a well-done document to review pharmacologic treatment of Type 2 diabetes mellitus and it collects the new evidence that endorses of SGLT2i and GLP1-RA use. Practical recommendations of metformin use are also reflected.
  MedlineGoogle Scholar
• 23. Scheen AJ. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30(5), 359–371 (1996).
  Medline CASGoogle Scholar
• 24. Graham GG, Punt J, Arora M et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50(2), 81–98 (2011).
  Medline CASGoogle Scholar
• 25. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in Type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15(10), 569–589 (2019). • We chose this work because of its comprehensive review of pathways involved in the action of metformin.
  Medline CASGoogle Scholar
• 26. Wu T, Horowitz M, Rayner CK. New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Rev. Gastroenterol. Hepatol. 11(2), 157–166 (2017).
  Medline CASGoogle Scholar
• 27. Tucker G, Casey C, Phillips P, Connor H, Ward J, Woods H. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12(2), 235–246 (1981).
  Medline CASGoogle Scholar
• 28. Wu T, Thazhath SS, Bound MJ, Jones KL, Horowitz M, Rayner CK. Mechanism of increase in plasma intact GLP-1 by metformin in Type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res. Clin. Pract. 106(1), e3–e6 (2014).
  Medline CASGoogle Scholar
• 29. Wilcox T, De Block C, Schwartzbard Arthur Z, Newman Jonathan D. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists. J. Am. Coll. Cardiol. 75(16), 1956–1974 (2020).
  Medline CASGoogle Scholar
• 30. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 103(6), 491–497 (1997).
  Medline CASGoogle Scholar
• 31. Piera-Mardemootoo C, Lambert P, Faillie J-L. Efficacy of metformin on glycemic control and weight in drug-naive Type 2 diabetes mellitus patients: a systematic review and meta-analysis of placebo-controlled randomized trials. Thérapie doi: 10.1016/j.therap.2018.01.006 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 32. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 35(2), 446–454 (2012).
  Medline CASGoogle Scholar
• 33. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3), CD002966 (2005).
  MedlineGoogle Scholar
• 34. Hallsten K, Virtanen KA, Lonnqvist F et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed Type 2 diabetes. Diabetes 51(12), 3479–3485 (2002).
  Medline CASGoogle Scholar
• 35. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 323–329 (2014).
  Medline CASGoogle Scholar
• 36. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020).
  MedlineGoogle Scholar
• 37. Xu T, Brandmaier S, Messias AC et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with Type 2 diabetes. Diabetes Care 38(10), 1858–1867 (2015).
  Medline CASGoogle Scholar
• 38. Jager JD, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in Type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257(1), 100–109 (2005).
  MedlineGoogle Scholar
• 39. Preiss D, Lloyd SM, Ford I et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2(2), 116–124 (2014).
  Medline CASGoogle Scholar
• 40. Lin SH, Cheng PC, Tu ST, Hsu SR, Cheng YC, Liu YH. Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed Type 2 diabetes mellitus: a cohort study. PeerJ. 6, e4578 (2018).
  MedlineGoogle Scholar
• 41. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med. 256(1), 1–14 (2004).
  Medline CASGoogle Scholar
• 42. Saran R, Robinson B, Abbott KC et al. US renal data system 2018 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 73(3), A7–A8 (2019).
  MedlineGoogle Scholar
• 43. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes−2020. Diabetes Care 43(Suppl. 1), S135–S151 (2020).
  MedlineGoogle Scholar
• 44. Kwon S, Kim YC, Park JY et al. The long-term effects of metformin on patients with Type 2 diabetic kidney disease. Diabetes Care 43(5), 948–955 (2020).
  Medline CASGoogle Scholar
• 45. Lalau J-D, Kajbaf F, Bennis Y, Hurtel-Lemaire A-S, Belpaire F, Broe MED. Metformin treatment in patients with Type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 41(3), 547–553 (2018).
  Medline CASGoogle Scholar
• 46. Rajani R, Pastor-Soler NM, Hallows KR. Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease. Curr. Opin. Nephrol. Hypertens. 26(5), 375–383 (2017).
  Medline CASGoogle Scholar
• 47. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 121(2), 149–157.e2 (2008).
  Medline CASGoogle Scholar
• 48. American Diabetes Association. 3. Prevention or delay of Type 2 diabetes: standards of medical care in diabetes—2020. Diabetes Care 43(Suppl. 1), S32–S36 (2020).
  MedlineGoogle Scholar
• 49. Griffin SJ, Bethel MA, Holman RR et al. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol. Assess. Winch. Engl. 22(18), 1–64 (2018).
  Google Scholar
• 50. Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc. Diabetol. 18(1), 54 (2019).
  MedlineGoogle Scholar
• 51. Petrie JR, Chaturvedi N, Ford I et al. Cardiovascular and metabolic effects of metformin in patients with Type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5(8), 597–609 (2017).
  Medline CASGoogle Scholar
• 52. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp. Clin. Endocrinol. Diabetes 121(1), 27–31 (2013).
  Medline CASGoogle Scholar
• 53. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of Metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338(26), 1876–1880 (1998).
  Medline CASGoogle Scholar
• 54. Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. (3), CD003053 (2003).
  MedlineGoogle Scholar
• 55. Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 60(9), 1639–1647 (2017).
  Medline CASGoogle Scholar
• 56. Aljofan M, Riethmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Sci. OA 5(8), FSO410 (2019).
  Medline CASGoogle Scholar
• 57. Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an anticancer agent. Trends Pharmacol. Sci. 39(10), 867–878 (2018).
  Medline CASGoogle Scholar
• 58. Pereira FV, Melo ACL, Low JS et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 9(40), 25808–25825 (2018).
  MedlineGoogle Scholar
• 59. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27(12), 2184–2195 (2016).
  Medline CASGoogle Scholar
• 60. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag. Res. 11, 3295–3313 (2019).
  Medline CASGoogle Scholar
• 61. Lv Z, Guo Y. Metformin and its benefits for various diseases. Front. Endocrinol. 11, 191 (2020).
  MedlineGoogle Scholar
• 62. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352(9131), 854–865 (1998). • It is a classical trial that supports metformin use and analyze cardiovascular outcomes.
  MedlineGoogle Scholar
• 63. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008).
  Medline CASGoogle Scholar
• 64. Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with Type 2 diabetes mellitus. Arch. Intern. Med. 169(6), 616–625 (2009).
  Medline CASGoogle Scholar
• 65. Hong J, Zhang Y, Lai S et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with Type 2 diabetes and coronary artery disease. Diabetes Care 36(5), 1304–1311 (2013).
  Medline CASGoogle Scholar
• 66. Maruthur NM, Tseng E, Hutfless S et al. Diabetes medications as monotherapy or metformin-based combination therapy for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164(11), 740–751 (2016).
  MedlineGoogle Scholar
• 67. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc. Diabetol. 18(1), 96 (2019).
  MedlineGoogle Scholar
• 68. Bergmark Brian A, Bhatt Deepak L, McGuire Darren K et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction. Circulation 140(12), 1004–1014 (2019).
  Medline CASGoogle Scholar
• 69. Roumie CL, Chipman J, Min JY et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and Reduced kidney function. JAMA 1–11 (2019).
  MedlineGoogle Scholar
• 70. Varas-Lorenzo C, Margulis AV, Pladevall M et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc. Disord. 14, 129 (2014).
  MedlineGoogle Scholar
• 71. Tseng C. Metformin use is associated with a lower risk of hospitalization for heart failure in patients with Type 2 diabetes mellitus: a retrospective cohort analysis. J. Am. Heart Assoc. 8(21), e011640 (2019). • A good retrospective cohort to review the potential role of metformin in reducing heart failure hospitalization.
  MedlineGoogle Scholar
• 72. Vantrimpont P, Rouleau JL, Wun C-C et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study fn1fn1 this study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J. Am. Coll. Cardiol. 29(2), 229–236 (1997).
  Medline CASGoogle Scholar
• 73. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 39(33), 3021–3104 (2018).
  MedlineGoogle Scholar
• 74. Wulffelé MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of Type 2 diabetes. Diabetes Care 25(12), 2133–2140 (2002).
  Medline CASGoogle Scholar
• 75. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. J. Br. Diabet. Assoc. 24(4), 350–358 (2007).
  Medline CASGoogle Scholar
• 76. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed Type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet Lond. Engl. 394(10208), 1519–1529 (2019).
  Medline CASGoogle Scholar
• 77. Rosenstock J, Chuck L, González-Ortiz M et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve Type 2 diabetes. Diabetes Care 39(3), 353–362 (2016).
  MedlineGoogle Scholar
• 78. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for Type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 66(5), 446–456 (2012).
  Medline CASGoogle Scholar
• 79. Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combination of empagliflozin and metformin in patients with Type 2 diabetes. Diabetes Care 39(10), 1718–1728 (2016).
  Medline CASGoogle Scholar
• 80. Gu J, Meng X, Guo Y et al. The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Sci. Rep. 6(1), 32714 (2016).
  Medline CASGoogle Scholar
• 81. Freeman VS. Glucose and hemoglobin A _1c. Lab. Med. 45(1), e21–e24 (2014).
  Google Scholar
• 82. 6. Glycemic targets: standards of medical care in diabetes—2020. 43, 11 (2020).
  Google Scholar
• 83. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 Years: overview. Diabetes Care 37(1), 9–16 (2014).
  Medline CASGoogle Scholar
• 84. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 159(4), 262–274 (2013).
  MedlineGoogle Scholar
• 85. Hinnen D. Glucagon-like peptide 1 receptor agonists for Type 2 diabetes. Diabetes Spectr. 30(3), 202–210 (2017).
  MedlineGoogle Scholar
• 86. Zelniker Thomas A, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J. Am. Coll. Cardiol. 75(4), 422–434 (2020).
  Medline CASGoogle Scholar
• 87. Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in Type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc. Diabetol. 17(1), 157 (2018).
  Medline CASGoogle Scholar
• 88. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (1), CD002967 (2010).
  Google Scholar
• 89. Longato E, Camillo BD, Sparacino G, Gubian L, Avogaro A, Fadini GP. Cardiovascular outcomes of Type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res. Care. 8(1), e001451 (2020).
  MedlineGoogle Scholar
• 90. Chow CK, Meng Q. Polypills for primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 16(10), 602–611 (2019).
  MedlineGoogle Scholar